Stock (Symbol) |
Stryker (SYK) |
Stock Price |
$99 |
Sector |
| Healthcare |
Data is as of |
| February 2, 2016 |
Expected to Report |
| Apr 19 – Apr 25 |
Company Description |
Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.Source: Thomson Financial |
Sharek’s Take |
One Year Chart |
In retrospect, I should have picked up some shares of Stryker when it dipped with the stock market this month. It got down to around 15-16x earnings. Last qtr the company had 4% revenue growth and 8% profit growth, and SYK beat the street by a penny. But next qtr’s profit growth estimate declined slightly from 12% to 8%. Annual Profit Estimates have remained steady the past few qtrs. |
Fair Value |
My Fair Value on this stock is 17x earnings. I feel SYK is right where it should be. |
Bottom Line |
Stryker has been trending up the past five years, and with investors appreciating consistent growth with high certainty — something Stryker delivers — this trend could continue. Still, I feel SYK is fairly valued at this juncture, but larger conservative accounts will appreciate the safety, certainty and consistency Stryker provides to portfolios. |
Power Rankings |
Growth Stock Portfolio
N/AAggressive Growth Portfolio N/AConservative Stock Portfolio N/A |

Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.
In retrospect, I should have picked up some shares of Stryker when it dipped with the stock market this month. It got down to around 15-16x earnings. Last qtr the company had 4% revenue growth and 8% profit growth, and SYK beat the street by a penny. But next qtr’s profit growth estimate declined slightly from 12% to 8%. Annual Profit Estimates have remained steady the past few qtrs.
My Fair Value on this stock is 17x earnings. I feel SYK is right where it should be.
Stryker has been trending up the past five years, and with investors appreciating consistent growth with high certainty — something Stryker delivers — this trend could continue. Still, I feel SYK is fairly valued at this juncture, but larger conservative accounts will appreciate the safety, certainty and consistency Stryker provides to portfolios.